RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwire - May 19, 2008) - Adherex Technologies Inc. (AMEX:ADH)(TSX:AHX), a biopharmaceutical company devoted to solving problems for patients with cancer, announced today the publication of an abstract on the phase I/II study of ADH-1 in combination with isolated limb infusion melphalan as a treatment for melanoma. The abstract was prepared for the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting, which takes place May 30 - June 3, 2008 in Chicago, IL.
